Zobrazeno 1 - 10
of 28
pro vyhledávání: '"Chadi Saifan"'
Autor:
Deborah Stephens, Jennifer R. Brown, Shuo MA, Michael Wang, Carol Moreno, Tadeusz Robak, Don Stevens, Shane Lee, Chadi Saifan, Emily Hsu, Sima Patel, Jan Burger
Publikováno v:
HemaSphere, Vol 7, p e4171997 (2023)
Externí odkaz:
https://doaj.org/article/2db4836b4b48477cbe42372b14c56f0e
Autor:
Mazyar Shadman, Bhavini Srivastava, Sima Patel, Chadi Saifan, Monika Salkar, Bruno Emond, Priyanka Gogna, Ameur Manceur, Marie-Helene Lafeuille, Deborah Stephens
Publikováno v:
HemaSphere, Vol 7, p e24922b0 (2023)
Externí odkaz:
https://doaj.org/article/84610cca2a88495694bedd9f4e9c3430
Autor:
Inmaculada de la Torre, Masayoshi Harigai, Joel M Kremer, Edward C Keystone, Maher Issa, Christina Dickson, Josh Rancourt, Thomas Melby, Yoshitaka Isaka, Anabela Cardoso, Chadi Saifan
Publikováno v:
RMD Open, Vol 6, Iss 3 (2020)
Objective To characterise changes in selected haematological parameters following once-daily oral baricitinib dosing.Methods Data were pooled from eight randomised clinical trials (four phase 3, three phase 2, one phase 1b) and one long-term extensio
Externí odkaz:
https://doaj.org/article/a4233ce845114923aee5548ee591ccb3
Publikováno v:
Case Reports in Medicine, Vol 2013 (2013)
Background. Sudden sensorineural hearing loss (SSHL) caused by opiate abuse or overuse has been well documented in the medical literature. Most documented case reports have involved either heroin or hydrocodone/acetaminophen. Recently, case reposts o
Externí odkaz:
https://doaj.org/article/271150516dea4ad4b398cbaec1dfcddb
Publikováno v:
Case Reports in Medicine, Vol 2013 (2013)
Background. Alport's syndrome is an X-linked hereditary disorder affecting the glomerular basement membrane associated with ocular and hearing defects. In women, the disease is much less severe compared to that in men. However, women with Alport's sy
Externí odkaz:
https://doaj.org/article/fcaaf35c635745c9a334666ae5ac2fd6
Autor:
Dennis Brinker, Josef S Smolen, Mo Daojun, Terence Rooney, Anabela Cardoso, Wen Shuo Wu, Tsutomu Takeuchi, Jinglin Zhong, Chadi Saifan, Kevin L. Winthrop, Mark C. Genovese, Gerd R Burmester, Maher Issa
Publikováno v:
The Lancet Rheumatology. 2:e347-e357
Summary Background Baricitinib is an oral selective inhibitor of Janus kinase (JAK) 1 and JAK2, approved for the treatment of patients with active rheumatoid arthritis. Because baricitinib, like other disease-modifying antirheumatic drugs, is used ch
Autor:
Tsutomu Takeuchi, Anabela Cardoso, Maher Issa, Michael E. Weinblatt, C. Walls, Gerd R Burmester, Peter C. Taylor, Sarah Witt, Chadi Saifan, Xin Zhang, Terence Rooney, Miguel A. González-Gay, Claudia A. Salinas
Publikováno v:
Arthritis & Rheumatology (Hoboken, N.j.)
Arthritis Rheumatol. 2019 Jul;71(7):1042-1055
UCrea Repositorio Abierto de la Universidad de Cantabria
Universidad de Cantabria (UC)
Arthritis Rheumatol. 2019 Jul;71(7):1042-1055
UCrea Repositorio Abierto de la Universidad de Cantabria
Universidad de Cantabria (UC)
Objective To assess the frequency of cardiovascular and venous thromboembolic events in clinical studies of baricitinib, an oral, selective JAK1 and JAK2 inhibitor approved in more than 50 countries for the treatment of moderately‐to‐severely act
Autor:
Yoshitaka Isaka, Inmaculada de la Torre, Tom W J Huizinga, Maher Issa, Masayoshi Harigai, C. Dickson, Joel M. Kremer, Ronald F. van Vollenhoven, Jonathan Kay, Jon T. Giles, Anabela Cardoso, Edward C. Keystone, Thomas Melby, Chadi Saifan, Josh Rancourt
Publikováno v:
RMD open, 6(3):e001370. BMJ Publishing Group
RMD Open, 6(3):e001370. BMJ Publishing Group
RMD Open
RMD Open, Vol 6, Iss 3 (2020)
RMD Open, 6(3). BMJ PUBLISHING GROUP
Kay, J, Harigai, M, Rancourt, J, Dickson, C, Melby, T, Issa, M, De La Torre, I, Isaka, Y, Cardoso, A, Saifan, C, Keystone, E C, Van Vollenhoven, R F, Giles, J T, Huizinga, T W J & Kremer, J M 2020, ' Changes in selected haematological parameters associated with JAK1/JAK2 inhibition observed in patients with rheumatoid arthritis treated with baricitinib ', RMD Open, vol. 6, no. 3, e001370 . https://doi.org/10.1136/rmdopen-2020-001370
RMD Open, 6(3):e001370. BMJ Publishing Group
RMD Open
RMD Open, Vol 6, Iss 3 (2020)
RMD Open, 6(3). BMJ PUBLISHING GROUP
Kay, J, Harigai, M, Rancourt, J, Dickson, C, Melby, T, Issa, M, De La Torre, I, Isaka, Y, Cardoso, A, Saifan, C, Keystone, E C, Van Vollenhoven, R F, Giles, J T, Huizinga, T W J & Kremer, J M 2020, ' Changes in selected haematological parameters associated with JAK1/JAK2 inhibition observed in patients with rheumatoid arthritis treated with baricitinib ', RMD Open, vol. 6, no. 3, e001370 . https://doi.org/10.1136/rmdopen-2020-001370
ObjectiveTo characterise changes in selected haematological parameters following once-daily oral baricitinib dosing.MethodsData were pooled from eight randomised clinical trials (four phase 3, three phase 2, one phase 1b) and one long-term extension.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7f8d0d4734d836240ee902e1db4d772e
https://doi.org/10.1136/rmdopen-2020-001370
https://doi.org/10.1136/rmdopen-2020-001370
Autor:
Atsushi Nishikawa, Josef S Smolen, Yoshitaka Isaka, Maher Issa, Kevin L. Winthrop, Terence Rooney, Naotsugu Akashi, Tsutomu Takeuchi, Chadi Saifan, Yoshiya Tanaka, T. Ishii, Masayoshi Harigai
Objectives: Baricitinib is a selective oral inhibitor of JAK1/JAK2 for patients with moderately-to-severely active rheumatoid arthritis (RA). Baricitinib’s safety profile in Japanese patients was evaluated using six studies (five Ph2/Ph3 trials, on
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c3623a7819ff2b15eaf86bfb7b773cfe
Autor:
Dennis Brinker, Josef S Smolen, Daojun Mo, Jinglin Zhong, Tsutomu Takeuchi, Wen-Shuo Wu, Terence Rooney, Mark C. Genovese, Kevin L. Winthrop, Anabela Cardoso, Chadi Saifan, Gerd R Burmester, Maher Issa
Publikováno v:
Poster Presentations.
Background: Baricitinib (bari), is an oral, selective inhibitor of Janus kinase (JAK) 1/JAK 2, to treat moderately to severely active RA in adults. Objectives: To update bari’s safety profile with data from an additional Phase (Ph) 3 trial and on-g